RAND: Medicare should weigh cost in coverage decisions
The agency that oversees the Medicare program should be able to consider the cost effectiveness of drugs and medical devices when making coverage determinations, according to a new report by the RAND Corporation. But study authors acknowledge that this recommendation — a significant change from current practice in which the Centers for Medicare & Medicaid Services is barred from considering cost – has little chance of being implemented because it would require Congressional action. "My impression is that changing Medicare will be very difficult. It may have to wait until more people believe we're in a crisis," said Steve Garber, a RAND senior economist.
- Sharp HealthCare Leaves Pioneer ACO Program
- Acute Kidney Injury Gets New Focus
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Interventional Radiology No Longer a Sub-Specialty
- NFP Hospitals' Revenue Growth at 'All-Time Low'
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- MA an Insurance Proving Ground for Providers
- mHealth Tackles Readmissions
- Targeting Self-Insured Populations
- PCI: Concerns Mount About Appropriateness